- Home
- MGNX vs BCV Comparison
MGNX vs BCV Comparison
Compare MGNX & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BCV
- Stock Information
- Founded
- MGNX 2000
- BCV 1971
- Country
- MGNX United States
- BCV United States
- Employees
- MGNX N/A
- BCV N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BCV Finance/Investors Services
- Sector
- MGNX Health Care
- BCV Finance
- Exchange
- MGNX Nasdaq
- BCV Nasdaq
- Market Cap
- MGNX 97.2M
- BCV 92.7M
- IPO Year
- MGNX 2013
- BCV N/A
- Fundamental
- Price
- MGNX $1.36
- BCV $17.88
- Analyst Decision
- MGNX Hold
- BCV
- Analyst Count
- MGNX 9
- BCV 0
- Target Price
- MGNX $5.33
- BCV N/A
- AVG Volume (30 Days)
- MGNX 378.7K
- BCV 26.3K
- Earning Date
- MGNX 05-13-2025
- BCV 01-01-0001
- Dividend Yield
- MGNX N/A
- BCV 8.13%
- EPS Growth
- MGNX N/A
- BCV N/A
- EPS
- MGNX N/A
- BCV N/A
- Revenue
- MGNX $154,050,000.00
- BCV N/A
- Revenue This Year
- MGNX N/A
- BCV N/A
- Revenue Next Year
- MGNX $45.52
- BCV N/A
- P/E Ratio
- MGNX N/A
- BCV N/A
- Revenue Growth
- MGNX 255.31
- BCV N/A
- 52 Week Low
- MGNX $0.99
- BCV $14.09
- 52 Week High
- MGNX $5.77
- BCV $18.11
- Technical
- Relative Strength Index (RSI)
- MGNX 39.88
- BCV 58.38
- Support Level
- MGNX $1.44
- BCV $17.76
- Resistance Level
- MGNX $1.58
- BCV $18.09
- Average True Range (ATR)
- MGNX 0.11
- BCV 0.26
- MACD
- MGNX -0.02
- BCV -0.02
- Stochastic Oscillator
- MGNX 17.65
- BCV 47.60
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.